



SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by

Yale School of Medicine, Human and Translational Immunology Program

“Anti-malaria immunity by self-amplifying RNA encoding *Plasmodium* MIF”

Richard Bucala, MD, PhD

Waldemar Von Zedtwitz Professor of Medicine (Rheumatology), and Professor of Pathology and Epidemiology & Public Health (Microbial Diseases)

Chief, Section of Rheumatology, Allergy & Immunology

Program in Human and Translational Immunology, Yale School of Medicine

Date: Tuesday, September 17, 2019 at 4pm

Location: The Anlyan Center – TAC N203

Seminar Host: Dr. Paula Kavathas

Course Director: Dr. Stephanie Eisenbarth and Dr. Carrie Lucas

*There is no corporate support for this activity. This activity is not supported by any educational grants.
This course will fulfill the licensure requirement set forth by the State of Connecticut*

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will understand:

1. The basis for malaria immune evasion
2. How parasite orthologous MIF proteins prevent cell mediated immunity
3. How self-amplifying RNAs can be exploited for vaccines

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Richard Bucala: Received royalties from Biogen-IDEA, Ferring AG, Baxter Healthcare and Debiopharm SA; Dr. Bucala or family members own equity in Abbott, Abbvie, Amgen, Biogen, Bioverativ, Deciphera, Eli Lilly, Exact Sciences, GSK, J&J, Merck, MIFCOR, Novartis, Pfizer, Promedior, Quest, Stryker and Zimmer.

Stephanie Eisenbarth: None

Carrie Lucas: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs